Hyponatremia in cirrhosis: Risk factors and prognostic value

##plugins.themes.academic_pro.article.sidebar##

Published Sep 19, 2016
Download
pdf
Vol. 94 No. 5 (2016): Issue May 2016

##plugins.themes.academic_pro.article.main##

Rym Ennaifer
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Myriam Cheikh
Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Rafika El Elj
Houda Ben Nejma
Wassila Bougassas
Najet Bel Hadj

Abstract

Abstract
Background : Hyponatremia is the most common electrolyte abnormality encountered in cirrhotic patients. Recent studies have shown that hyponatremia was correlated with severity of cirrhosis and associated with increased risk of complications and mortality. However this relationship is still unclear. The aims of the present study were to search predictive factors for hyponatremia in cirrhosis and to assess its prognostic value.
Methods : We performed a retrospective study, including consecutive cirrhotic patients admitted to our department between January 2011 and April 2014. Patients and cirrhosis characteristics were studied. Serum sodium levels were determined at admission. The cutoff level of 130 mmol/l was chosen because it is widely accepted to define hyponatremia in patients with cirrhosis. Predictive factors of hyponatremia development and its impact on the outcome (cirrhosis complications and survival) were evaluated.
Results : We included 143 cirrhotic patients: 67 females (46.9%) and 76 males (53.1%) with a mean age of 58 years. Etiology of cirrhosis was mainly viral (56.7%). Child-Pugh stage was B in 41.2% and C in 25.9%. Mean MELD score was 15 [6-40]. The prevalence of dilutional hyponatremia as defined by a serum sodium concentration ≤130 mmol/L or ≤135 mmol/L was 10.5% and 31.4% respectively. Serum sodium level ≤130 mmol/L was strongly associated with severity of liver function impairment as indicated by Child-Pugh C (OR=7.84;p<0.001), and MELD score> 16 (OR=6.76; p=0.001).
Survival without complications was reduced in patients with hyponatremia but was only significant if a serum sodium concentration ≤135 mmol/L was considered (p=0.012). Survival without hepatic encephalopathy and without hepatorenal syndrome was significantly reduced in patients with hyponatremia (p<0.001 for both).
Global survival was also reduced in patients with hyponatremia at 1 year: 22.5% versus 68.7%, as well as mean global survival: 8.3 versus 32.8 months (p<0.0001).
Conclusion : Low serum sodium level was correlated with severity of cirrhosis.  Hyponatremia was a negative prognostic factor associated with increased short-term morbi-mortality.

Keywords:

Cirrhosis, hyponatremia, complications, mortality

##plugins.themes.academic_pro.article.details##

References

  1. Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135-43.
  2. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115-24.
  3. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-26.
  4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
  5. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851-8.
  6. Sersté T, Gustot T, Rautou PE, Francoz C, Njimi H, Durand F, et al. Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. J Hepatol. 2012;57:274-80.
  7. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851-64.
  8. Angeli P, Wong F, Watson H, Ginès P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535-42.
  9. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA et al. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J Intern Med. 2009;24:106-12.
  10. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336-43.
  11. Shaikh S, Mal G, Khalid S, Baloch GH, Akbar Y. Frequency of hyponatremia and its influence on liver cirrhosis-related complications. J Pak Med Assoc.2010;60:116-20.
  12. Qureshi MO, Khokhar N, Saleem A, Niazi TK. Correlation of hyponatremia with hepatic encephalopathy and severity of liver disease. J Coll Physicians Surg Pak. 2014;24:135-7.
  13. Porcel A, Díaz F, Rendón P, Macías M, Martín-Herrera L, Girón-González JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med. 2002;162:323-8.
  14. Umemura T, Shibata S, Sekiguchi T, Kitabatake H, Nozawa Y, Okuhara S, et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatol Res. 2014;in press.
  15. Tzamouranis D, AlexopoulouA, Dourakis SP, StergiouGS. Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia. Ann Gastroenterol. 2012;25:254-7.
  16. Jenq CC, Tsai MH, Tian YC, Chang MY, Lin CY, Lien JM, et al. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010;44:220-6.
  17. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatremia for the hospital outcome of cirrhotic patients. Dig Liver Dis. 2000;32:605-10.
  18. Somberg JC, Molnar J. Therapeutic approaches to the treatment of edema and ascites: the use of diuretics. Am J Ther. 2009;16:98-101.
  19. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643-53.
  20. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794-9.
  21. Mohan S, Gu S, Parikh A, Radhakrishnan J. Prevalence of hyponatremia and association with mortality: results from NHANES. Am J Med. 2013;126:1127-37.
  22. Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One. 2013;8:e80451.
  23. Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283-90.